Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments by Animesh Gopal (18521180)

Subjects:

The difference of BMD between 2019 and 2022 classify by grop of urinary camium levels measured in 2019. by Aroon La-up (14095691)

Subjects:

Non-linear relationship between urinary cadmium and bone mineral density from the adjusted restricted cubic splines model. by Aroon La-up (14095691)

Subjects:

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. by Aroon La-up (14095691)

Subjects:

Linear Mixed-Effects Model analysis of bone mineral density changes in relation to urinary cadmium levels in a 3-Year Period. by Aroon La-up (14095691)

Subjects:

Data. by Aroon La-up (14095691)

Subjects:

Stratified analysis of the association between urinary cadmium and bone mineral density, by sex. by Aroon La-up (14095691)

Subjects:

Association between baseline urinary cadmium and the three-year change in bone mineral density (ΔBMD). by Aroon La-up (14095691)

Subjects:

Characteristics of the study participants for continuous variables. by Aroon La-up (14095691)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects: